Advanced search
Publication Cover
Substance Abuse Volume 35, 2014 - Issue 2
Journal homepage
926
Views
4
CrossRef citations to date
0
Altmetric
COMMENTARIES

Progress in Addiction Treatment: From One-Size-Fits-All to Medications and Treatment Matching

George E. WoodyPenn/VA Addiction Treatment & Research Center, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania and the Treatment Research Institute, Philadelphia, Pennsylvania, USACorrespondence[email protected]
, MD
Pages 110-113 | Published online: 12 May 2014

REFERENCES

  • Musto DF. The American Disease: Origins of Narcotic Control. 3rd ed. New York: Oxford University Press; 1999.
  • Alcoholics Anonymous. The Big Book. . 4th ed. Center City, Minnesota: Alcoholics Anonymous World Services, Inc., Hazelden Press; 2001.
  • Main T. The hospital as a therapeutic institution. Bull Menninger Clin. 1946;10:66–70.
  • De Leon G. Therapeutic communities for addictions: a theoretical framework. Int J Addict. 1995;30:1603–1645.
  • Dole VP, Nyswander M. Successful treatment of 750 criminal addicts. JAMA. 1968;26:2708–2710.
  • Dole VP, Nyswander ME. A medical treatment for diacetylmorphine (heroin) addiction. JAMA. 1965;193:646–650.
  • Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York: Springer-Verlag; 1991.
  • Woody GE. Visual disturbances experienced by hallucinogenic drug abusers while driving. Am J Psychiatry. 1970;127:683–686.
  • Woody GE, O’Brien CP, Rickels K. Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry. 1975;132:447–450.
  • Nunes EV, Quitkin FM, Donovan S, et al. Imipramine treatment of opiate dependent patients with depressive disorders: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:153–160.
  • McLellan AT, Luborsky L, Woody GE, O’Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980;168:26–33.
  • McLellan AT, Luborsky L, Woody GE, et al. Predicting response to alcohol and drug abuse treatments: role of psychiatric severity. Arch Gen Psychiatry. 1983;40:620–625.
  • Woody GE, McLellan AT, Luborsky L, et al. Psychiatric severity as a predictor of benefits from psychotherapy the Penn-VA study. Am J Psychiatry. 1984;141:1172–1177.
  • Rounsaville BJ, Glazer W, Wilber CH, et al. Short-term interpersonal psychotherapy in methadone maintained opiate addicts. Arch Gen Psychiatry. 1983;39:161–166.
  • Kessler RC, Nelson CB, McGonagle KA, et al. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996;66:17–31.
  • Umbricht-Schneiter A, Ginn DH, Pabst KM, et al. Providing medical care to methadone clinic patients: referral vs. on-site care. Am J Public Health. 1994;84:207–210.
  • Altice FL, Bruce RD, Lucas GM, et al.; BHIVES Collaborative. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J. Acquir Immune Defic Syndr. 2011;56(Suppl 1):S22–S32 doi: 10.1097/QAI.0b013e318209751e.
  • Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York: Guilford; 1991.
  • Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiaty. 1992;49:876–880.
  • Johnson BA, Rosenthal N, Capece JA, et al.; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298:1546–1552.
  • Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51–63.
  • Rosner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Soyka M. Acamprosate for alcohol dependence. Cochrane Database Syst Rev. 2010;9:CD004332. doi: 10.1002/14651858.CD004332.pub2.
  • Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA. 2005;293:1617–1625.
  • Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind placebo-controlled, multicenter randomised trial. Lancet. 2011;377:1506–1513.
  • Oslin DW, Berretini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology. 2003;28:1546–1552.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.